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Two mutations (G8363A and A8296G) in the mtDNA (mitochon-
drial DNA) tRNALys gene have been associated with severe mito-
chondrial diseases in a number of reports. Their functional signi-
ficance, however, remains unknown. We have already shown that
homoplasmic cybrids harbouring the A8296G mutation display
normal oxidative phosphorylation, although the possibility of a
subtle change in mitochondrial respiratory capacity remains an
open issue. We have now investigated the pathogenic mechanism
of another mutation in the tRNALys gene (G8363A) by repopu-
lating an mtDNA-less human osteosarcoma cell line with mito-
chondria harbouring either this genetic variant alone or an unusual
combination of the two mutations (A8296G + G8363A). Cybrids
homoplasmic for the single G8363A or the A8296G + G8363A
mutations have defective respiratory-chain enzyme activities and
low oxygen consumption, indicating a severe impairment of the
oxidative phosphorylation system. Generation of G8363A cybrids
within a wild-type or the A8296G mtDNA genetic backgrounds
resulted in an important alteration in the conformation of the
tRNALys, not affecting tRNA steady-state levels. Moreover, mutant
cybrids have an important decrease in the proportion of amino-
acylated tRNALys and, consequently, mitochondrial protein syn-
thesis is greatly decreased. Our results demonstrate that the patho-
genicity of the G8363A mutation is due to a change in the
conformation of the tRNA that severely impairs aminoacylation
in the absence of changes in tRNA stability. The only effect
detected in the A8296G mutation is a moderate decrease in the
aminoacylation capacity, which does not affect mitochondrial
protein biosynthesis.
Key words: aminoacylation, mitochondrial encephalomyopathy
with lactic acidosis and stroke-like episodes (MELAS), myoclonic
epilepsy with ragged-red fibres (MERRF), mitochondrial DNA
(mtDNA) mutation, mitochondrial tRNALys gene.
INTRODUCTION
Mitochondria generate most of the cellular ATP by OXPHOS
(oxidative phosphorylation). The OXPHOS system is composed
of five different complexes embedded in the inner mitochon-
drial membrane (complexes I–V) and two small electron carriers,
namely ubiquinone and cytochrome c [1,2]. Mammalian mito-
chondria are endowed with their own semi-autonomous genetic
system [mtDNA (mitochondrial DNA)] that encodes a limited
number of essential genes for OXPHOS biogenesis: 13 polypep-
tides of complex I [ND1–ND6 and ND4L (subunits 1–6 and 4L of
NADH:ubiquinone oxidoreductase], complex III (cytochrome b),
complex IV (cytochrome c oxidase subunits I–III) and complex V
(ATPases 6–8), as well as the RNA components of the translational
apparatus, two rRNAs (12 and 16 S) and 22 tRNAs. The rest of
the structural subunits of the OXPHOS system and all the factors
involved in OXPHOS assembly and regulation, mtDNA ex-
pression and mtDNA maintenance are encoded in the nucleus,
translated into cytoplasmic ribosomes and imported to their final
mitochondrial location [3]. Therefore OXPHOS defects can be
produced by mutations in mitochondrially encoded genes, nuclear
genes encoding OXPHOS subunits or in nuclear genes encoding
factors directly or indirectly involved in OXPHOS regulation
[4–6].
To date, more than 200 mtDNA mutations have been impli-
cated in the pathogenesis of mitochondrial diseases with defec-
tive OXPHOS, including large mtDNA rearrangements and point
mutations in tRNA, rRNA and protein-coding genes [7]. Mito-
chondrial diseases are usually multisystemic disorders and pro-
duce devastating encephalomyopathies since they affect predom-
inantly high energy-demanding tissues such as the nervous system
and skeletal and cardiac muscles [8]. Mutations in protein-coding
genes affect a single complex of the OXPHOS system. In contrast,
mutations in tRNA genes impair the mitochondrial translation
system and therefore affect four of the five OXPHOS complexes,
producing combined enzyme deficits of the respiratory chain
[9]. Two point mutations, A3243G in the tRNALeu(UUR) gene and
A8344G in the tRNALys gene, associated with two well-defined
clinical syndromes, MELAS (mitochondrial encephalomyopathy
with lactic acidosis and stroke-like episodes) and MERRF (myo-
clonic epilepsy with ragged-red fibres) respectively, are relatively
frequent and have been extensively characterized [10–13]. How-
ever, the relationship between genotype (mutation) and pheno-
type (clinical symptoms) has not been understood so far [8]. Het-
erogeneity is paramount: the same mutation can be associated with
diverse clinical manifestations and different mutations can pro-
duce the same symptoms. Dosage and distribution of the altered
tRNAs in the different tissues of the organism cannot simply
account for these phenomena. In addition, the pathogenic mech-
anisms of the different mtDNA mutations are not fully understood
and have not been studied in detail for most of the mutations
described so far.
Abbreviations used: FBS, fetal bovine serum; DMEM, Dulbecco’s modified Eagle’s medium; MELAS, mitochondrial encephalomyopathy with lactic
acidosis and stroke-like episodes; MERRF, myoclonic epilepsy with ragged-red fibres; mtDNA, mitochondrial DNA; OXPHOS, oxidative phosphorylation.
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We were the first to report on a family segregating the MERRF
syndrome in association with a double mutation, A8296G and
G8363A, in the tRNALys gene [14]. The A8296G mutation was
practically homoplasmic in all the investigated family members,
whereas the proportion of the G8363A mutation correlated with
the severity of the phenotype. Both mutations disrupt highly
conserved base pairs in the aminoacyl stem of the tRNALys. The
A8296G mutation has also been independently described in asso-
ciation with Type II (non-insulin-dependent) diabetes mellitus
[15,16], hypertrophic cardiomyopathy [17] and the MELAS
syndrome [18]. On the other hand, the G8363A mutation had
already been associated with MERRF [19], maternally inherited
cardiomyopathy and hearing loss in two pedigrees [20], and with
spinocerebellar ataxia and multiple symmetric lipomatosis [21].
More recently, we reported that transmitochondrial hybrids homo-
plasmic for the A8296G mutation had a normal OXPHOS function
[22], a finding which challenges a clear-cut pathogenic role. In
the present study, we have generated and extensively characterized
transmitochondrial hybrids homoplasmic for the single G8363A
mutation and the A8296G/G8363A double mutation. We have
found that the A8296G mutation decreases moderately the amino-
acylation capacity of the tRNALys, although it does not have
consequences for mitochondrial protein biosynthesis. In contrast,
biochemical and molecular results demonstrate that the G8363A
mutation impairs mitochondrial protein synthesis and compro-
mises severely the function of OXPHOS by altering the confor-
mation of the tRNALys and decreasing drastically its aminoacyl-
ation capacity. This phenotype is not modified by the presence
of the A8296G mutation.
MATERIALS AND METHODS
Cell lines and media
Two fibroblast cell lines were established from diagnostic skin
biopsies obtained from the mother of an MERRF patient har-
bouring the A8296G-G8363A double mutation [14] and from
a patient suffering from cerebellar ataxia and lipomatosis har-
bouring approx. 80% of the G8363A mutation in the mtDNA
tRNAlys gene [21]. Cells were grown in DMEM (Dulbecco’s
modified Eagle’s medium), supplemented with 10% FBS (fetal
bovine serum) and 50 µg/ml uridine. The human osteosarcoma
cell line 143 B (TK−) was grown in DMEM supplemented with
10% FBS, 100 µg/ml bromodeoxyuridine and 50 µg/ml uridine.
Its mtDNA-less derived 206 cell line (ρ0) was grown in DMEM
supplemented with 5% FBS and 50 µg/ml uridine.
Establishment of transmitochondrial hybrids
The patients’ derived enucleated fibroblasts (0.5 × 106 cells) were
fused to 106 ρ0-206 cells as described previously [23]. Trans-
mitochondrial hybrid clones (cybrids) were grown in DMEM sup-
plemented with 10% dialysed FBS and 100 µg/ml bromodeoxy-
uridine. Individual clones were isolated and the mtDNA was
analysed for both A8296G and G8363A transitions by the AciI/
Asp700 RFLP (restriction-fragment-length polymorphism) me-
thod as described in [14].
Respiratory function assays
The rate of oxygen consumption was measured as described pre-
viously [22] at 37 ◦C using a Clark-type platinum polarographic
electrode using 3–5 × 106 exponentially intact cells growing in
2 ml of complete DMEM without glucose. To assess respiratory
chain enzymes in cells, approx. 5 × 106 cells were harvested by
trypsinization, washed twice with phosphate buffer and resus-
pended in 2 ml of Mops/sucrose buffer. Digitonin (200 µg) was
added and incubation was performed on ice for 5 min. After
centrifugation at 5000 g for 3 min, the pellet was resuspended in
0.5 ml of 10 mM potassium phosphate buffer (pH 7.4) and freeze–
thawed twice just before evaluating the enzyme complexes. The
activities of rotenone-sensitive NADH-coenzyme Q1 reductase
(complex I), succinate dehydrogenase (part of complex II), anti-
mycin-sensitive ubiquinol cytochrome c reductase (complex III),
cytochrome c oxidase (complex IV) and citrate synthase were
measured in duplicate in each assay, and expressed in terms of
nmol of substrate · min−1 · (mg of protein)−1. We did not normalize
the respiratory chain activities for the activity of citrate synthase
since this matrix enzyme is also expressed at high levels in
the ρ0 mitochondria of the host cells. Protein concentration was
measured by the method of Lowry as described in [22].
Quantification of mitochondrial DNA
To extract total DNA, cells were pooled, washed with PBS, resus-
pended in 1 ml of lysis buffer (100 mM NaCl, 0.5% SDS, 10 mM
Tris and 25 mM EDTA, pH 8.0) and incubated in the presence of
0.2 mg/ml proteinase K at 42 ◦C for 24 h. DNA was extracted by
standard methods [24]. Quantification of mtDNA in fibroblasts,
cybrid cell lines and ρ0 cells was performed by slot-blot and
Southern-blot analyses. As a probe, we used an [α-32P]dCTP-
labelled long mtDNA PCR-amplified fragment (using an oligo-
nucleotide from nucleotide positions 13420–13443 as forward
primer and an oligonucleotide from nt 8200–8225 as reverse pri-
mer). As loading control, the same membranes were incubated
with an [α-32P]dCTP-labelled 18 S rRNA probe. Quantitative ana-
lysis was performed by phosphoimager detection.
Quantification of mitochondrial tRNAs
Total RNA (5 µg) extracted from cybrid cell lines was incubated at
90 ◦C for 5 min, electrophoresed through a 12% polyacrylamide–
7 M urea gel in 1 × TBE (Tris/borate/EDTA) buffer and electro-
blotted on to a Zeta-probe membrane at 300 mA for 30 min in 1 ×
TAE (Tris/acetate/EDTA) buffer. Hybridization was performed at
42 ◦C for 24 h in 6 × SSC (1 ×SSC = 0.15 M NaCl/0.015 M so-
dium citrate), 1 × Denhardt’s solution, 0.5%SDS, 0.05% sodium
pyrophosphate and 100 µg/ml denatured salmon sperm DNA.
The tRNALys was detected using a synthetic 20-mer oligo-
nucleotide (spanning mtDNA nucleotide positions 8361–8342),
which had been labelled with [γ -32P]ATP at its 5′-end. After
hybridization, the blot was washed twice for 30 min with 6 × SSC,
0.1% SDS and 0.05% sodium pyrophosphate at 42 ◦C. The
membrane was stripped out and rehybridized under the same con-
ditions with a [γ -32P] 5′-end-labelled 21-mer oligonucleotide cor-
responding to mtDNA positions 597–577 of the tRNAPhe gene.
The ratio of tRNALys to tRNAPhe was calculated by quantification
of the respective signals either by densitometry or phosphoimager
analysis.
Single-strand conformational analysis of mitochondrial tRNAs
Total RNA (8 µg) extracted from cybrid cell lines was electro-
phoresed through a 6% non-denaturing polyacrylamide (60:1)
gel in 1 × TBE buffer as described previously [25]. To detect
the tRNALys and tRNAPhe, we used the same labelled probes and
hybridization conditions described above.
Analysis of the aminoacylation of mitochondrial tRNAs
Total RNA from cells was extracted under acidic conditions to
preserve aminoacylated tRNAs using a previously described
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Table 1 Respiratory function assays in cybrid cell lines
Results are expressed as means +− S.D.; each individual clone was analysed twice. *P < 0.001 and **P < 0.01 indicate statistical significance with respect to wild-type (wt) and 100 % A8296G cell
lines respectively, and ***P < 0.05 indicates statistical significance with respect to 100 % A8296G cell lines, by the two-tailed, Mann–Whitney U test for unpaired samples. Oxygen consumption is
expressed in terms of fmol · min−1 · cell−1 and mean specific enzyme activity is expressed in terms of (nmol of substrate) · min−1 · (mg of protein)−1.
Mean specific enzyme activity
Cell line Oxygen consumption Complex I Complex II Complex III Complex IV Citrate synthase
Wt (n = 6) 4.6 +− 0.9 14.3 +− 1.2 10.8 +− 3.5 104.0 +− 25 54 +− 8 200 +− 26
8363 (n = 2) 0 5.6 +− 0.8*, *** 10.2 +− 1.6 15.0 +− 4.5** 5.1 +− 2.8* 188 +− 22
8296 (n = 9) 4.5 +− 0.8 11.8 +− 3.4 9.1 +− 4.0 93.1 +− 24 57 +− 3 183 +− 22
8296/8363 (n = 6) 0.1 +− 0.1* 3.9 +− 1.0* 11.1 +− 3.0 5.5 +− 4.5* 6.4 +− 2.6* 188 +− 22
143B (n = 3) 4.4 +− 0.5 18.1 +− 3.5 14.1 +− 3.7 102 +− 23 70 +− 20 189 +− 30
143B/206 (ρ0) (n = 3) 0 1.5 +− 0.4 11.1 +− 0.8 2 +− 1.8 1 +− 0.8 167 +− 15
method [26] with minor modifications. Total RNA (3 µg) was
electrophoresed through an 8% non-denaturing polyacrylamide
(29:1) gel in 0.1 M sodium acetate (pH 5.0) buffer at 100–200 V
for 18–20 h, with the buffer being continuously recirculated at
4 ◦C. To deacylate tRNAs, an aliquot of total RNA was boiled
for 10 min (pH 8.0) before electrophoresis. Then, the gel was
electroblotted on to a Zeta-probe membrane and hybridized with
specific tRNALys and tRNAPhe probes.
Mitochondrial protein synthesis
To analyse the translation products of mitochondrial genes in
the different cybrid cell lines, subconfluent cultures were labelled
with [35S]methionine in the presence of 100 µg of emetine · (ml of
medium)−1 by the method of Chomyn [27] with minor modi-
fications. Cells were labelled with 125 µCi of [35S]methionine for
2 h, washed with phosphate buffer and harvested. After centri-
fugation at 400 g, cells were resuspended in lysis buffer [20 mM
Tris/HCl (pH 7.5), 0.1% SDS, 5 mM MgCl2 and 1 mM PMSF].
Total protein (100 µg) was electrophoresed and detected by auto-
radiography.
RESULTS
Generation of transmitochondrial cybrids
In a previous study, we generated transmitochondrial cybrids by
fusing the human mtDNA-less ρ0-206 cell line with fibroblasts
obtained from an MERRF patient containing >95% of the
A8296G combined with 50% G8363A mutations in mtDNA,
as described in the Materials and methods section. More than
60 clones were isolated, most of them being homoplasmic for
the A8296G mutation and the remainder containing different pro-
portions of the A8296G-G8363A double mutation. Several clones
were selected for further biochemical and molecular character-
ization, essentially homoplasmic (>99%) for the single A8296G
mutation [22] or homoplasmic (>99%) for both A8296G and
G8363A mutations (the present study). Since the A8296G mu-
tation is virtually homoplasmic in the patient’s derived skin
fibroblasts, it was impractical to continue the isolation of clones
to obtain cybrids homoplasmic for the G8363A mutation alone. To
achieve this, we generated additional transmitochondrial cybrids
fusing the human mtDNA-less ρ0-206 cell line with fibroblasts
obtained from a patient suffering from spinocerebellar ataxia
and multiple lipomas, containing approx. 80% of the G8363A
mutation. We isolated several independent clones homoplasmic
for the G8363A mutation. We used as control a cybrid cell line
obtained by the fusion of the ρ0-206 cell line with fibroblasts
homoplasmic for wild-type mtDNA. The genetic characterization
of the different cybrid cell lines was performed by PCR–RFLP
as described previously [14] (results not shown). All the clones
contained similar amounts of mtDNA as clones containing wild-
type mtDNA, suggesting that there is no negative selection against
the mutation.
The G8363A mutation produces severe biochemical defects
of the respiratory chain in cybrid cell lines
We investigated the respiratory capacity of at least two inde-
pendent clones harbouring either wild-type mtDNA or the specific
kind of mutations by measuring the specific activities of the
mitochondrial respiratory chain complexes I–IV and the rate of
oxygen consumption in intact cells. We have reported previously
that homoplasmic single A8296G mutant clones showed normal
values in the respiratory chain activities and oxygen consumption,
comparable with those of homoplasmic wild-type mtDNA clones
[22]. In contrast, cybrid clones homoplasmic for the G8363A
single mutant or A8296G-G8363A double mutant showed a clear
defect of the mitochondrial respiratory chain complexes I, III
and IV, with a mean residual activity of 36% (complex I) and
10% (complexes III and IV) in mutant clones when compared
with wild-type lines or homoplasmic >95% A8296G clones
(Table 1). Oxygen consumption was severely impaired in these
clones (Table 1; mean decrease was 95%, P < 0.001).
Mitochondrial tRNALys steady-state levels
and conformation analysis
The potential effect of the G8363A mutation on the steady-state
level of the tRNALys was investigated by Northern-blot analysis.
Total RNA was extracted from mutants and wild-type cybrids,
electrophoresed on agarose–formaldehyde gels and probed with a
DNA fragment containing the tRNALys gene labelled with [α-32P]-
dCTP. As control, we have quantified the steady-state level of the
tRNAPhe using a specific tRNAPhe probe (Figure 1). The ratios
between the signals obtained with a tRNALys gene probe and a
tRNAPhe gene probe used as control were similar in all cases, in-
dicating that neither the G8363A mutation alone nor the A8296G-
G8363A double mutations significantly decrease the stability
of the tRNALys. To find out whether the mutations introduce
changes in the conformation of the tRNA, we performed non-
denaturing single-strand analysis as described in the Materials
and methods section. In contrast with the lack of effect observed
in tRNA stability, the G8363A mutation produces a drastic shift in
the mobility of the tRNALys, and practically the entire tRNA
shows a delayed migration (Figure 2). Interestingly, the tRNALys
harbouring the A8296G-G8363A double mutations showed a
slightly increased delay in the electrophoretic migration compared
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Figure 1 Steady-state levels of tRNALys in transmitochondrial wild-type and
mutant cybrid cell lines
Total RNA extracted from various cybrid cell lines was analysed by Northern blotting using
specific tRNALys and tRNAPhe probes. Equal amounts of RNA (5 µg) were fractionated on 12 %
polyacrylamide–7 M urea gels, transferred on to a nylon membrane, hybridized with the tRNALys
and tRNAPhe radiolabelled probes and autoradiographed. Signals from at least four independent
experiments from each cybrid cell line were quantified by densitometric and/or phosphoimager
analyses. No statistically significant differences were detected (the Kruskal–Wallis method).
Figure 2 tRNA conformational analysis
Total RNA (8 µg) extracted from the various cybrid cell lines was electrophoresed on a 6 %
polyacrylamide gel under non-denaturing conditions, transferred on to a nylon membrane,
hybridized with the tRNALys radiolabelled probe and autoradiographed. The same filter was
rehybridized with the tRNAPhe probe and analysed as described above.
with the tRNALys harbouring the single G8363A mutation. This
result clearly demonstrated that the conformation of the tRNALys
is not changed by the A8296G mutation and its alteration is due
to the G8363A mutation. Furthermore, the A8296G mutation
has some synergistic role in the change induced by the G8363A
mutation.
Synthesis of mitochondrial proteins
Figure 3 shows a representative experiment to investigate the
effect of the mutations on the mitochondrial translation capacity.
In contrast with homoplasmic A8296G cybrids [22], homoplasmic
G8363A and double mutant A8296G-G8363A cybrids showed a
marked decrease in the incorporation of [35S]methionine into the
mitochondrially encoded polypeptides. A landmark of previously
characterized tRNALys mutations is the presence of abnormal
polypeptides generated by premature termination of translation.
In particular, one of them, designated pMERRF, is derived from
premature termination of COI (subunit 1 of cytochrome c oxidase)
and migrates below the ND4 polypeptide [10]. Although we have
not detected a prominent truncated product in mutant cells, in
the mitochondrial translation pattern of G8363A and A8296G-
G8363A cybrids there are relative increases in the radioactive
signal in the region that migrates below the ND4 polypeptide
(indicated by an asterisk in Figure 3), suggesting that, in the
mutant cybrids, there are some accumulations of truncated poly-
peptides. These results confirm that the behaviour of the mtDNA
harbouring the A8296G mutation is similar to wild-type and
Figure 3 Mitochondrial protein synthesis in transmitochondrial wild-type
and mutant cybrid cell lines
Cells were labelled with [35S]methionine in the presence of emetine as described in the Materials
and methods section. A fluorogram of the mitochondrial translation products after fractionation
on an SDS 15–20 % polyacrylamide gel is shown. The position of different mitochondrial
polypeptides is indicated; *, presence of potential abnormal translation products in mutant
cybrid cells.
indicate that the G8363A mutation has a profound effect on mito-
chondrial protein synthesis.
tRNALys aminoacylation
To determine whether the G8363A mutation impairs the amino-
acylation capacity of the tRNALys, we isolated, from purified mi-
tochondria, total RNA under conditions that preserved the amino-
acylated tRNAs. Total RNAs were electrophoresed on 6.5%
polyacrylamide–8 M urea gels, electroblotted on to nylon mem-
branes and hybridized with specific tRNALys and tRNAPhe probes
as described in the Materials and methods section. Aminoacylated
and non-aminoacylated tRNALys can clearly be observed under
these conditions in both wild-type and mutant cybrids, although
the mobility of the wild-type tRNALys and Lys-tRNALys is some-
what slower compared with the mutant ones (Figure 4A). When
the RNA samples were heated and electrophoresed under the same
conditions, a total conversion of the aminoacylated-tRNALys in its
deacylated form was observed (results not shown). As a con-
trol of the loading of the gel, we rehybridized the filters with a
tRNAPhe-specific probe. Under these conditions, the acylated and
deacylated tRNAPhe forms were not resolved (results not shown).
Quantitative densitometric analysis of the autoradiograms
showed a moderate but significant decrease in the percentage of
the aminoacylated form of the tRNALys harbouring the A8296G
mutation (61%; Figure 4B) when compared with tRNALys wild-
type (76%). The tRNALys harbouring the G8363A mutation had a
drastic reduction in the amount of its aminoacylated form (18%),
indicating that a change in the conformation of the tRNA produced
by the G8363A mutation impairs drastically its aminoacylation
capacity. The presence of the A8296G mutation did not act
synergistically, since the same percentage of aminoacylated
forms was present in the tRNALys containing the two mutations
(A8296G + G8363A).
DISCUSSION
To date, 12 different mutations in the mtDNA tRNALys gene have
been described in association with an array of mitochondrial
diseases [7]. We first documented a A8296G-G8363A double
mutant in the mtDNA tRNALys gene in a family with MERRF [14].
Both mutations have been reported in isolation in independent
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Figure 4 Aminoacylation of tRNALys in transmitochondrial wild-type and
mutant cybrid cell lines
(A) Total mitochondrial RNA was extracted under acidic conditions and electrophoresed on an
8 % non-denaturing polyacrylamide gel as described in the Materials and methods section.
RNAs were transferred on to a nylon membrane, hybridized with a specific tRNALys-radiolabelled
probe and autoradiographed. (B) Signals corresponding to the aminoacylated and deacylated
forms of the tRNALys obtained in at least three independent experiments were densitometrically
quantified. Results are expressed as a percentage of the aminoacylated form +− S.D.; *P < 0.05,
protected least significant difference test.
pedigrees [15–21]. Interestingly, we have recently reported that
homoplasmic A8296G cybrid clones have normal respiratory
chain function, as shown by oxygen consumption, lactate produc-
tion and respiratory chain enzyme activities [22]. However, the
possibility that the mutation might cause subtle defects of oxi-
dative phosphorylation or a defect depending on the nuclear back-
ground was not fully excluded.
To investigate the pathogenic role of the G8363A mutation,
we have generated and extensively characterized cybrid clones
harbouring homoplasmic levels of mutant mtDNAs in two dif-
ferent mtDNA tRNALys genetic backgrounds, i.e. wild-type and
A8296G. Homoplasmic G8363A as well as G8363A + A8296G
mutants caused a drastic decrease in the activities of the respira-
tory-chain complexes I, III and IV, which contain mtDNA-
encoded subunits, whereas the activity of complex II (containing
only nuclear DNA-encoded subunits) remained normal. Consis-
tently, we observed a marked decrease in oxygen consumption and
in mitochondrial protein synthesis in clones harbouring homo-
plasmic G8363A and A8296G-G8363A mutations, whereas oxy-
gen consumption and the mitochondrial synthetic capacity in
clones homoplasmic for the single A8296G mutation were simi-
lar to wild-type. The G8363A mutation produced a drastic
conformational change in the tRNALys that is slightly increased
by the presence of the A8296G mutation. Furthermore, there was
evidence of a significant decrease (57–59%) in the aminoacyl-
ation capacity of the tRNALys harbouring the G8363A mutation,
of the same range as detected in the tRNALys harbouring the
A8296G-G8363A double mutant. In contrast, the presence of
the A8296G mutation decreases only moderately (15–17%) the
aminoacylation capacity of the tRNALys.
These results indicate that a decrease in the aminoacylation
capacity is, at least in part, the pathogenic molecular mechanism
causing the collapse in mitochondrial protein synthesis and
OXPHOS defects of the G8363A mutation. This pathogenic
mechanism is not significantly modified by the presence of the
A8296G mutation. Aminoacylation defects have been found in
other tRNALys point mutations analysed in transmitochondrial
cybrids. The well-established pathogenic A8344G mutation in
the tRNALys gene produces a mild decrease in tRNA stability and
tRNA aminoacylation, decreasing tRNALys lysine charging capa-
city in mitochondria [10]. In addition, the G8313A mutation in
the tRNALys produces a strong decrease in the tRNA stability and
decreases its aminoacylation capacity [28]. In contrast, neither the
G8363A mutation nor the A8296G-G8363A mutation alters
the steady-state level of the tRNALys, indicating that the stability
of the tRNALys is not altered by the presence of the mutations. In
addition, the steady-state levels of the flanking mRNAs (COII and
ATPases 6–8) are similar in wild-type and mutant cybrids (results
not shown), suggesting that the processing of the heavy-strand
pre-mRNA is correct at the tRNALys site.
If our results demonstrate unequivocally that the G8363A mu-
tation is pathogenic, the potential pathogenicity of the A8296G
mutation is still puzzling. The high degree of conservation of
this specific nucleotide in the tRNALys gene during evolution,
together with the fact that several pedigrees are found in which the
mutation segregates with the affected phenotype and the absence
of the mutation in a large number of ethnically matched normal
controls contrast with the apparent lack of a disease-causative
role in a commonly used experimental cell system. The modest
decrease in the aminoacylation capacity of the tRNALys that we
observed does not suffice to affect the respiratory function. It is
possible that the mutation achieves its pathogenic effects when
present within a specific nuclear background or, alternatively,
that it impairs mitochondrial physiology by a mechanism not
related to the OXPHOS function. In this regard, it has been
observed that cells with the A3243G mutation, a well-known
pathogenic mutation in the mitochondrial tRNALeu(UUR) gene,
produced an impaired mitochondrial translation machinery that
depends heavily on the specific nuclear background (reviewed in
[29]). The A3243G mutation is related to a profound decrease
in the steady-state level and aminoacylation capacity of the
tRNALeu(UUR) in some cases [11,30], whereas it decreases the as-
sociation of mRNA with mitoribosomes in other cases [31].
However, aminoacylation is practically unaffected in some other
cell lines and impaired mitochondrial protein synthesis occurs
because of misreading of the phenylalanine codon due to a de-
crease in the modification of the U present in the wobble position
of the anti-codon [32]. Moreover, it has been described in a
different cell system that a defect in processing of the pre-mRNA
at the tRNALeu(UUR) site leads to the accumulation of an inter-
mediary transcript that might contribute to the impairment of
mitochondrial protein synthesis [13,33]. Finally, and most interes-
tingly, an RNA circularization technique has demonstrated that
the decrease in total and/or aminoacylated tRNALeu(UUR levels
also varies considerably in vivo when muscle biopsied samples
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from MELAS patients are used [34]. This does not apply to
biopsied material from MERRF patients harbouring mutations
in the tRNALys gene [34]. These results suggest that trans-acting
factors and/or compensatory mechanisms that depend on the
nuclear background modulate the expression of the mtDNA mu-
tations. In this regard, established cybrid cell lines with defined
molecular pathogenic mechanisms may be critical for identifying
these factors in the near future [29].
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